文献速递头颈部肿瘤放疗姑息放疗与转移瘤

阿片类药物与多模式镇痛治疗头颈癌(OPTIMAL-HN):一项随机临床试验结果

Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial.
PubMed 文献 · Radiother Oncol · 2025-03-05

OPTIMAL-HN是一项开放标签、非劣效性随机临床试验,纳入49例接受根治性放疗或放化疗且出现≥4/10放射性黏膜炎疼痛的头颈癌患者,1:1随机分组至单纯阿片类药物组(25例)或多模式镇痛组(24例)。主要终点放疗最后一周平均疼痛评分两组分别为5.1(95%CI 4.1-6.1)和4.9(95%CI 3.8-5.9),非劣效性p=0.039,优效性p=0.72;分析入组至放疗后6周所有疼痛评分时,多模式镇痛显示非劣效性和优效性(非劣效性p=0.0024,优效性p<0.001)。作者认为多模式镇痛应被视为头颈癌放疗患者有效的镇痛方式。

要点

  • 放疗最后一周平均疼痛评分:阿片组5.1 vs 多模式镇痛组4.9,非劣效性p=0.039。
  • 入组至放疗后6周所有疼痛评分分析中,多模式镇痛兼有非劣效性和优效性。
  • 多模式镇痛组1例因急性肾损伤入院,可能与镇痛方案相关。

核心结论

  • 多模式镇痛在放疗最后一周管理放射性黏膜炎疼痛方面对单纯阿片类药物非劣效,在分析放疗后时间段时显示优效性。
  • 作者据此认为多模式镇痛应被视为接受放疗的头颈癌患者的一种有效镇痛方式。

研究设计与样本

  • OPTIMAL-HN(ClinicalTrials.gov标识NCT04221165)是一项开放标签、非劣效性随机临床试验,纳入接受根治性放疗或放化疗且出现≥4/10中度放射性黏膜炎疼痛的头颈癌患者,按1:1随机分组并按放疗vs放化疗分层。

主要发现

  • 共入组49例患者,阿片类镇痛组25例,多模式镇痛组24例,中位随访4.2个月。
  • 主要终点放疗最后7天平均疼痛评分:阿片组5.1(95%CI 4.1-6.1) vs 多模式镇痛组4.9(95%CI 3.8-5.9),非劣效性p=0.039,优效性p=0.72。
  • 分析入组至放疗后6周所有疼痛评分,多模式镇痛对单纯阿片类药物同时显示非劣效性和优效性(非劣效性p=0.0024,优效性p<0.001)。
  • 多模式镇痛组1例因急性肾损伤入院,可能与镇痛方案相关。
  • 两组在所有其他次要终点方面相似。

关键数值与推荐

  • 多模式镇痛方案包括普瑞巴林、对乙酰氨基酚、萘普生,必要时加用阿片类药物。
  • 非劣效性检验在主要终点达到统计学意义(p=0.039),优效性检验未达统计学意义(p=0.72)。

临床怎么用

  • 作者认为多模式镇痛应被视为接受放疗的头颈癌患者的一种有效镇痛方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation-induced mucositis (RIM) pain confers substantial morbidity for head and neck cancer (HNC) patients undergoing radiotherapy (RT) or chemoradiotherapy (CRT). With no well-established standard treatment, OPTIMAL-HN aimed to demonstrate the non-inferiority of multimodal analgesia (MMA; analgesic medications with different mechanisms of action) to opioid analgesia alone. METHODS: OPTIMAL-HN (ClinicalTrials.gov identifier: NCT04221165) was an open-label, non-inferiority, randomized clinical trial. We enrolled HNC patients receiving curative-intent RT/CRT and experiencing moderate ≥ 4/10 RIM pain. We randomized 1:1, stratified by RT vs. CRT, to opioids alone (standard arm) or MMA (pregabalin, acetaminophen, naproxen, and opioids if required). The primary endpoint was mean pain score (range: 0-10) during the last week of RT. Secondary endpoints included mean weekly opioid use, duration of opioid requirement, quality of life, weight loss, and toxicity. All analyses were pre-specified, including testing for superiority if non-inferiority was demonstrated. RESULTS: Forty-nine patients were enrolled, 25 in the opioid analgesia arm and 24 in the MMA arm. Median follow-up was 4.2 months. The primary endpoint, mean pain score during the last 7 days of RT, was 5.1 (95 % confidence interval [CI]: 4.1-6.1) in the opioid arm and 4.9 (95 % CI: 3.8-5.9) in the MMA arm (non-inferiority p = 0.039, superiority p = 0.72). Analyzing all pain scores from enrollment to 6-weeks post-RT, MMA demonstrated both non-inferiority and superiority compared to opioids alone (non-inferiority p = 0.0024, superiority p < 0.001). One patient in the MMA arm was admitted with acute kidney injury, possibly related to the analgesic regimen. Arms were similar for all other secondary endpoints. CONCLUSIONS: MMA demonstrates non-inferiority to opioid analgesia alone in managing RIM pain during the last week of RT and superiority when analyzing the post-RT time period. MMA should, therefore, be considered an effective mode of analgesia for HNC patients receiving RT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zayed S, Lang P, Read N, et al. Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial. Radiother Oncol. 2025. PMID: 40054624. doi:10.1016/j.radonc.2025.110831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。